Merck (MRK) Interest & Investment Income (2011 - 2013)
Merck (MRK) posted quarterly Interest & Investment Income of $57.0 million for Q1 2013, up 3.64% YoY from $55.0 million in Q1 2012, and up 3.64% sequentially from $55.0 million in Q4 2012.
Merck (MRK) Interest & Investment Income (2011 - 2013) Analysis & Trends
Merck has disclosed Interest & Investment Income across 3 years of filings, most recently posting $57.0 million for Q1 2013.
- In Q1 2013, Interest & Investment Income rose 3.64% year-over-year to $57.0 million; the TTM figure through Mar 2013 stood at $214.0 million (changed N/A YoY), while the FY2012 annual figure was $1.8 billion, changed 0.0% from the prior year.
- Interest & Investment Income grew to $57.0 million in Q1 2013, from $55.0 million in the prior quarter.
- Over the last five years, Interest & Investment Income for MRK reached as high as $57.0 million in Q1 2013 and fell as low as $32.0 million in Q3 2011.
- The 3-year median for Interest & Investment Income is $51.0 million (2012), against an average of $48.2 million.
- Annual changes were most pronounced in 2012 — Interest & Investment Income jumped 46.88% — and 2013, when it gained 3.64%.
- A 3-year view of Interest & Investment Income shows it stood at $43.0 million in 2011, then gained by 27.91% to $55.0 million in 2012, then grew by 3.64% to $57.0 million in 2013.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $57.0 million, $55.0 million, and $47.0 million for Q1 2013, Q4 2012, and Q3 2012 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 229.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -645.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 73.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 57.00 Mn |
| Dec 31, 2012 | 55.00 Mn |
| Sep 30, 2012 | 47.00 Mn |
| Mar 31, 2012 | 55.00 Mn |
| Dec 31, 2011 | 43.00 Mn |
| Sep 30, 2011 | 32.00 Mn |